Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.67 |
| ▸ | GLO1 | Q04760 | 5/20 | 0.59 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5332441 | 0.89 | PTGS1 (0.68) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL5332446 | 0.89 | PTGS1 (0.68) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL18009307 | 0.88 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL14236615 | 0.88 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL420277 | 0.88 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL2017370 | 0.88 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL19579378 | 0.87 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL13561367 | 0.87 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL138746 | 0.87 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL16377441 | 0.87 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9931313-B2 | Methods of treating proliferative disorders with malate or derivatives thereof | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2018-04-03 | — | — | US | claimed |
| US-20150056215-A1 | METHODS OF TREATING PROLIFERATIVE DISORDERS WITH MALATE OR DERIVATIVES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2015-02-26 | — | — | US | claimed |
| WO-2013152193-A2 | METHODS OF TREATING PROLIFERATIVE DISORDERS WITH MALATE OR DERIVATIVES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2013-10-10 | — | — | WO | claimed |
| US-20130209488-A1 | METHODS AND COMPOSITIONS FOR MALIC ENZYME 2 (ME2) AS A TARGET FOR CANCER THERAPY | BETH ISRAEL DEACONESS MEDICAL CENTER, INC (US) | 2013-08-15 | — | — | US | claimed |
| WO-2012019154-A2 | METHODS AND COMPOSITIONS FOR MALIC ENZYME 2 (ME2) AS A TARGET FOR CANCER THERAPY | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2012-02-09 | — | — | WO | claimed |
| US-9931313-B2 | Methods of treating proliferative disorders with malate or derivatives thereof | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9539323-B2 | Methods and compositions for malic enzyme 2 (ME2) as a target for cancer therapy | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150056215-A1 | METHODS OF TREATING PROLIFERATIVE DISORDERS WITH MALATE OR DERIVATIVES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20130209488-A1 | METHODS AND COMPOSITIONS FOR MALIC ENZYME 2 (ME2) AS A TARGET FOR CANCER THERAPY | BETH ISRAEL DEACONESS MEDICAL CENTER, INC (US) | 2013-08-15 | — | — | US | disclosed |
| WO-2012019154-A2 | METHODS AND COMPOSITIONS FOR MALIC ENZYME 2 (ME2) AS A TARGET FOR CANCER THERAPY | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110288052-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | FAS SECURED CREDITORS HOLDCO, LLC | 2011-11-24 | — | — | US | disclosed |
| EP-2386551-A1 | Novel compounds, pharmaceutical compositions containing same, and methods of use for same | Fasgen Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20100029761-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | FAS SECURED CREDITORS HOLDCO, LLC | 2010-02-04 | — | — | US | disclosed |
| US-7649012-B2 | Compounds, pharmaceutical compositions containing same, and methods of use for same | FASGEN, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090005435-A1 | Novel Compounds, Pharmaceutical Compositions Containing Same, and Methods of Use for Same | FAS SECURED CREDITORS HOLDCO, LLC | 2009-01-01 | — | — | US | disclosed |
| US-20060247302-A1 | Novel compounds, pharmaceutical compositions containing same, and methods of use for same | FASGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
| US-20060241177-A1 | Novel compounds, pharmaceutical compositions containing same, and methods of use for same | FAS SECURED CREDITORS HOLDCO, LLC | 2006-10-26 | — | — | US | disclosed |
| EP-0651636-B1 | CHEMOTHERAPY FOR CANCER | UNIV JOHNS HOPKINS (US) | 2002-10-02 | — | — | EP | disclosed |
| US-5759837-A | ANTITUMOR AGENTS AND ANTICARCINOGENIC AGENTS | JOHN HOPKINS UNIVERSITY (US) | 1998-06-02 | — | — | US | disclosed |
| US-5614551-A | Inhibitors of fatty acid synthesis as antimicrobial agents | THE JOHNS HOPKINS UNIVERSITY (US) | 1997-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056215-A1 | METHODS OF TREATING PROLIFERATIVE DISORDERS WITH MALATE OR DERIVATIVES THEREOF | MDH2, MDH1, ME1 | PTGS1 1096/4885GSTK1 1486/4885GLO1 457/4885 |
| US-20060241177-A1 | Novel compounds, pharmaceutical compositions containing same, and methods of use for same | CPT1B, CPT1A, CRAT | PTGS1 1152/4885GSTK1 3472/4885GLO1 1139/4885 |
| US-20060247302-A1 | Novel compounds, pharmaceutical compositions containing same, and methods of use for same | CPT1B, HCRTR2, CPT1A | PTGS1 554/4885GSTK1 3753/4885GLO1 3487/4885 |
| US-20110288052-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | C1S, C1R, MC2R | PTGS1 1476/4885GSTK1 4317/4885GLO1 3275/4885 |
| US-20100029761-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | NR1H4, CYP3A4, CYP4A11 | PTGS1 2839/4885GSTK1 4502/4885GLO1 4755/4885 |
| US-20090005435-A1 | Novel Compounds, Pharmaceutical Compositions Containing Same, and Methods of Use for Same | C1R, CNR1, CYP3A5 | PTGS1 1201/4885GSTK1 4760/4885GLO1 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.